Oregon Public Employees Retirement Fund Has $9.72 Million Stake in Boston Scientific Co. (NYSE:BSX)

Oregon Public Employees Retirement Fund raised its stake in shares of Boston Scientific Co. (NYSE:BSX) by 0.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 126,259 shares of the medical equipment provider’s stock after buying an additional 1,056 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Boston Scientific were worth $9,723,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of BSX. Sierra Summit Advisors LLC acquired a new stake in Boston Scientific in the fourth quarter worth $8,038,000. TD Asset Management Inc grew its stake in Boston Scientific by 10.7% in the fourth quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock valued at $93,417,000 after acquiring an additional 155,565 shares during the period. BI Asset Management Fondsmaeglerselskab A S raised its position in shares of Boston Scientific by 225.6% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock worth $7,237,000 after purchasing an additional 73,219 shares during the period. BDF Gestion acquired a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $3,570,000. Finally, Precision Wealth Strategies LLC acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $956,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Down 0.8 %

Shares of Boston Scientific stock opened at $81.14 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14. The business has a fifty day simple moving average of $77.12 and a two-hundred day simple moving average of $73.25. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $82.10. The company has a market capitalization of $119.04 billion, a price-to-earnings ratio of 68.18, a P/E/G ratio of 2.71 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. The company had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. Boston Scientific’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.53 EPS. Research analysts forecast that Boston Scientific Co. will post 2.4 EPS for the current year.

Insider Buying and Selling

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the transaction, the executive vice president now directly owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 20,949 shares of company stock valued at $1,627,877 over the last 90 days. 0.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on BSX shares. BTIG Research upped their target price on shares of Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Raymond James increased their price objective on Boston Scientific from $85.00 to $91.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 25th. Argus upped their price target on Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, May 28th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a research report on Thursday, July 25th. Finally, TD Cowen raised their target price on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $85.24.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.